Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss
Complaints allege the company overstated sonelokimab’s superiority, leading to an 89.9% stock collapse after Phase 3 results.
Overview
- Investor law firms including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Berger Montague, Howard G. Smith, and Faruqi & Faruqi are urging shareholders to seek lead-plaintiff status by December 15, 2025.
- The actions, filed in federal court with cases in the Southern District of New York, cover purchasers of MoonLake shares from March 10, 2024 through September 29, 2025.
- Complaints assert MoonLake promoted SLK’s Nanobody-based superiority while omitting that SLK and UCB’s BIMZELX target IL‑17A and IL‑17F and that no superior clinical benefit had been demonstrated.
- MoonLake’s September 29 Form 8‑K reported that intercurrent events in a higher‑than‑expected placebo arm prevented statistical significance on the VELA‑2 week‑16 primary endpoint.
- Following the Phase 3 disclosures, MoonLake shares fell 89.9% in one trading day, which plaintiffs cite as evidence of investor losses tied to the alleged misstatements.